Therapeutic antibodies company Elusys Therapeutics Inc reported on Wednesday the receipt of approval from the European Commission for the company's monoclonal antibody (mAb) anthrax antitoxin obiltoxaximab for the treatment of inhalations by anthrax.
The company said Obiltoxaximab is indicated for all age groups in combination with antibacterial drugs suitable for the treatment of inhalational anthrax due to Bacillus anthracis as well as post-exposure inhalation anthrax prophylaxis when alternative therapies are not available or appropriate.
This EU approval for obiltoxaximab will automatically become UK marketing authorization on 1 January 2021.
In conjunction, SFL Pharmaceuticals Deutschland GmbH will act as Marketing Authorization Holder (MAH) in the EU and UK. Obiltoxaximab has received approval under the brand name Anthim in the US and Canada. In the EU, obiltoxaximab will be approved under the brand name Obiltoxaximab SFL.
The EC's approval is based on data from the company's studies conducted with funding from US government agencies, including the Biomedical Advanced Research and Development Authority (BARDA), part of the US Office of the Assistant Secretary for Preparedness and Response. Department of Health and Human Services, the National Institutes of Health (NIH) and the US Department of Defense (DoD).
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data